CSL Seqirus mini oral: Transforming secondary prevention after MI: Imaging residual risk and targeting what remains
| Saturday, August 8, 2026 |
| 10:00 AM - 10:30 AM |
| Theatrette 6 (Exhibition Hall) |
Details
"Despite guideline-recommended therapy, CAD patients can continue to experience ischaemic events driven by residual plaque progression.1 This ongoing plaque progression highlights the significant residual risk gap.1 This session explores if plaque imaging can refine risk assessment and how targeted strategies, including VAZKEPA®, offer an opportunity to further reduce cardiovascular risk associated with mild-to-moderate hypertriglyceridaemia.*2,3,4
*VAZKEPA® is indicated to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk with elevated triglycerides (≥1.7 mmol/L) and established CV disease or diabetes, and at least one other CV risk factor.
CAD, coronary artery disease; CSANZ, Cardiac Society of Australia and New Zealand; CV, cardiovascular; MI, myocardial infarction; PBS, Pharmaceutical Benefits Scheme
1.Galli M, et al. Nat Rev Cardiol. 2026 Jul;23(7):500-523 2. VAZKEPA® Product Information. 3. Bhatt DL, et al. N Engl J Med 2019;380:11–22 (including suppl. appendix). 4. Pharmaceutical Benefits Scheme. VAZKEPA®. Available at: www.pbs.gov.au.
"
Speaker
Assoc Prof Adam J Nelson
Cardiologist
Victorian Heart Institute / Royal Adelaide Hospital
Transforming secondary prevention after MI: Imaging residual risk and targeting what Rremains
10:00 AM - 10:30 AMBiography
A/Prof Adam Nelson is an early career interventional cardiologist and clinical trialist dual-appointed to the Royal Adelaide and Queen Elizabeth Hospitals in addition to the University of Adelaide and the Victorian Heart Institute. Adam has a specific interest in understanding the barriers to vaccination of cardiovascular patients and developing implementation programs to overcome them.
Prof Peter Psaltis
Deputy Director, Co-leader, Lifelong Health Theme, Leader, Heart And Vascular Program, SAHMRI
South Australia Health and Medical Research Institute / Central Adelaide LHN / University of Australia
Transforming secondary prevention after MI: Imaging residual risk and targeting what remains
10:00 AM - 10:30 AMBiography
Professor Peter Psaltis is an academic Interventional and Preventative Cardiologist, holding a Level 3 National Heart Foundation Future Leader Fellowship. He has faculty positions with the Central Adelaide Local Health Network, the University of Adelaide, and the South Australian Health and Medical Research Institute (SAHMRI), where he is co-Deputy Director, co-leads the Lifelong Health Theme, and heads the Heart and Vascular Health Program. He is also Head of Interventional Cardiology at the Royal Adelaide Hospital. Peter’s research spans basic, translational, and clinical science. He has received over $24 million in competitive grant funding and has published over 250 peer-reviewed works. He has also supervised 15 PhD and 12 Honours students to completion, with outstanding outcomes.
